The company, which is slated to be acquired by ViroLogic during the fourth quarter, generated $515,000 in receipts for the three months ended June 30 compared with $405,000 in the year-ago quarter.
Second-quarter R&D spending shrank to $2.7 million from $4 million year over year.
Largely as a result, net loss decreased to $4.9 million, or $.13 per share, from $5.1 million, or $.14 per share, during the second quarter last year.
Aclara, based in
Click here for more information.